{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:55:02Z","timestamp":1787169302736,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Involuntary treatment for individuals who lack sufficient capacity to make informed decisions regarding treatment has been associated with increased rates of injectable antipsychotics, antipsychotic polytherapy, and\/or high doses. However, little is known about non-antipsychotic psychotropic prescription, or psychotropic medication burden as a more encompassing approach for people treated involuntarily. The aim of this study was to examine the relationship between Mental Health Act (MHA) status and psychotropic polypharmacy and\/or high-dose medication prescribing practices in an Australian inpatient mental health unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study of 800 adults discharged from a large metropolitan Queensland mental health unit was undertaken. Data was collected for 200 individuals, discharged on at least one psychotropic medicine, at four time periods; Cohort 1 (on or before 31st January 2014), Cohort 2 (2015), Cohort 3 (2016) and Cohort 4 (2017). The number of prescribed medicines and total daily doses were recorded and reviewed for alignment with current clinical guidelines. Participant demographics and clinical characteristics were compared by individual MHA status using chi-square test for categorical variables and analysis of variance for continuous variables. Associations between MHA status and prescribing practices (psychotropic polypharmacy and\/or high-dose prescribing) were assessed using bivariate and multivariate binomial logistic regression models. Age, gender, birth country, year of admission, admissions in previous 12\u2009months, primary diagnosis, ECT\/clozapine treatment, and other psychotropic medications were adjusted as covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Regression analysis found that compared to their voluntary counterparts, individuals treated involuntarily were 2.7 times more likely to be prescribed an antipsychotic at discharge, 8.8 times more likely to be prescribed more than one antipsychotic at discharge and 1.65 times more likely to be prescribed high-dose antipsychotic treatment at discharge. The adjusted model also found that they were half as likely to be prescribed an antidepressant at discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Implicit review of justifications for increased psychotropic medication burden (antipsychotic polypharmacy and high-doses) in those treated involuntarily is required to ensure clinical outcomes and overall quality of life are improved in this vulnerable group. Clearly documented medication histories, reconciliation at discharge and directions for medication management after discharge are necessary to ensure quality use of medicines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-020-02661-6","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T14:03:52Z","timestamp":1591884232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Is higher psychotropic medication burden associated with involuntary treatment under the Mental Health Act? A four-year Australian cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-674X","authenticated-orcid":false,"given":"Amanda J.","family":"Wheeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Profitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-4467","authenticated-orcid":false,"given":"Sara S.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Theodoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"2661_CR1","unstructured":"Australian Law Reform Commission. Equality, Capacity and Disability in Commonwealth Laws: Summary Report (ALRC124). Commonwealth of Australia; 2014. https:\/\/www.alrc.gov.au\/publication\/equality-capacity-and-disability-in-commonwealth-laws-alrc-124-summary\/ (accessed 30 March 2019)."},{"key":"2661_CR2","volume-title":"Powers and duties of psychiatrists in Australian and New Zealand mental health acts: a literature review","author":"Royal Australian and New Zealand College of Psychiatrists","year":"2017","unstructured":"Royal Australian and New Zealand College of Psychiatrists. Powers and duties of psychiatrists in Australian and New Zealand mental health acts: a literature review. Melbourne: RANZCP; 2017. https:\/\/www.ranzcp.org\/files\/resources\/college_statements\/mental-health-legislation-tables\/powers-and-duties-of-psychiatrists-in-australian-a.aspx (accessed 30 Mar 2019)."},{"key":"2661_CR3","unstructured":"Queensland Government. Mental Health Act 2016 (Act No.5 of 2016). 2016. https:\/\/www.legislation.qld.gov.au\/view\/pdf\/asmade\/act-2016-005 (accessed 30 Mar 2019)."},{"key":"2661_CR4","volume-title":"Mental health legislation and psychiatrists: putting the principles into practice","author":"Royal Australian and New Zealand College of Psychiatrists","year":"2017","unstructured":"Royal Australian and New Zealand College of Psychiatrists. Mental health legislation and psychiatrists: putting the principles into practice. Melbourne: RANZCP; 2017. https:\/\/www.ranzcp.org\/news-policy\/policy-submissions-reports\/document-library\/mental-health-legislation-and-psychiatrists-putti (accessed 30 Mar 2019)."},{"key":"2661_CR5","unstructured":"United Nations. Principles for the protection of persons with mental illness and the improvement of mental health care (General Assembly Resolution 46\/119 of 17 December 1991). Geneva; 1991. https:\/\/www.un.org\/documents\/ga\/res\/46\/a46r119.htm (accessed 20 Mar 2019)."},{"key":"2661_CR6","unstructured":"Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards: Standard 4 Medication Safety. 2017. updated 31st May 2018. https:\/\/www.nationalstandards.safetyandquality.gov.au\/4.-medication-safety (accessed 30 Mar 2019)."},{"issue":"4","key":"2661_CR7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1039856215626644","volume":"24","author":"S Dey","year":"2016","unstructured":"Dey S, Menkes DB, Obertova Z, Chaudhuri S, Mellsop G. Antipsychotic prescribing and its correlates in New Zealand. Australas Psychiatry. 2016;24(4):360\u20134.","journal-title":"Australas Psychiatry"},{"issue":"4","key":"2661_CR8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00406-007-0777-4","volume":"258","author":"TW Kallert","year":"2008","unstructured":"Kallert TW, Glockner M, Schutzwohl M. Involuntary vs. voluntary hospital admission. A systematic literature review on outcome diversity. Eur Arch Psychiatry Clin Neurosci. 2008;258(4):195\u2013209.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"2661_CR9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.apnu.2014.04.002","volume":"28","author":"L Gou","year":"2014","unstructured":"Gou L, Zhou JS, Xiang YT, Zhu XM, Correll CU, Ungvari GS, Chiu HF, Lai KY, Wang XP. Frequency of involuntary admissions and its associations with demographic and clinical characteristics in China. Arch Psychiatr Nurs. 2014;28(4):272\u20136.","journal-title":"Arch Psychiatr Nurs"},{"key":"2661_CR10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.psychres.2018.05.030","volume":"267","author":"MS Ritsner","year":"2018","unstructured":"Ritsner MS, Farkash H, Rauchberger B, Amrami-Weizman A, Zendjidjian XY. Assessment of health needs, satisfaction with care, and quality of life in compulsorily admitted patients with severe mental disorders. Psychiatry Res. 2018;267:541\u201350.","journal-title":"Psychiatry Res"},{"key":"2661_CR11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijlp.2016.02.034","volume":"47","author":"A Curley","year":"2016","unstructured":"Curley A, Agada E, Emechebe A, Anamdi C, Ng XT, Duffy R, Kelly BD. Exploring and explaining involuntary care: the relationship between psychiatric admission status, gender and other demographic and clinical variables. Int J Law Psychiatry. 2016;47:53\u20139.","journal-title":"Int J Law Psychiatry"},{"key":"2661_CR12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajp.2016.11.007","volume":"35","author":"NV Indu","year":"2018","unstructured":"Indu NV, Vidhukumar K, Sarma PS. Determinants of compulsory admissions in a state psychiatric hospital-case control study. Asian J Psychiatr. 2018;35:141\u20135.","journal-title":"Asian J Psychiatr"},{"issue":"11","key":"2661_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1192\/pb.26.11.411","volume":"26","author":"P Lelliott","year":"2002","unstructured":"Lelliott P, Paton C, Harrington M, Konsolaki M, Sensky T, Okocha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull. 2002;26(11):411\u20134.","journal-title":"Psychiatr Bull"},{"key":"2661_CR14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.psychres.2016.09.035","volume":"246","author":"J Campos Mendes","year":"2016","unstructured":"Campos Mendes J, Azeredo-Lopes S, Cardoso G. Patterns of antipsychotics' prescription in Portuguese acute psychiatric wards: a cross-sectional study. Psychiatry Res. 2016;246:142\u20138.","journal-title":"Psychiatry Res"},{"key":"2661_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12888-017-1295-1","volume":"17","author":"SS McMillan","year":"2017","unstructured":"McMillan SS, Jacobs S, Wilson L, Theodoros T, Robinson G, Anderson C, Mihala G, Wheeler AJ. Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points. BMC Psychiatry. 2017;17:139.","journal-title":"BMC Psychiatry"},{"issue":"S52","key":"2661_CR16","doi-asserted-by":"crossref","first-page":"s57","DOI":"10.1192\/bjp.195.52.s57","volume":"195","author":"TJ Lambert","year":"2009","unstructured":"Lambert TJ, Singh BS, Patel MX. Community treatment orders and antipsychotic long-acting injections. Br J Psychiatry. 2009;195(S52):s57\u201362.","journal-title":"Br J Psychiatry"},{"key":"2661_CR17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1440-1665.2000.00264.x","volume":"8","author":"T Callaly","year":"2000","unstructured":"Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australas Psychiatry. 2000;8:220\u20134.","journal-title":"Australas Psychiatry"},{"issue":"2","key":"2661_CR18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/ijcp.12276","volume":"68","author":"N Gisev","year":"2014","unstructured":"Gisev N, Bell J, Chen T. A retrospective study of psychotropic drug use among individuals with mental illness issued a community treatment order. Int J Clin Pract. 2014;68(2):236\u201344.","journal-title":"Int J Clin Pract"},{"key":"2661_CR19","doi-asserted-by":"crossref","unstructured":"John AP, Gee T, Alexander S, Ramankutty P, Dragovic M. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service. Australas Psychiatry. 2014;22(6):546\u2013550.","DOI":"10.1177\/1039856214546672"},{"issue":"6","key":"2661_CR20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s10488-007-0142-y","volume":"34","author":"MJ Sernyak","year":"2007","unstructured":"Sernyak MJ, Rosenheck R. Clinicians\u2019 reasons for deviations from recommended dosing practices for antipsychotic medications. Adm Policy Ment Health. 2007;34(6):540\u20137.","journal-title":"Adm Policy Ment Health"},{"issue":"1","key":"2661_CR21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2045125311430110","volume":"2","author":"P Grech","year":"2012","unstructured":"Grech P, Taylor D. Long-term antipsychotic polypharmacy: how does it start, why does it continue? Ther Adv Psychopharmacol. 2012;2(1):5\u201311.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"8","key":"2661_CR22","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","volume":"57","author":"MH Chakos","year":"2006","unstructured":"Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA. Special section on CATIE baseline data: baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006;57(8):1094\u2013101.","journal-title":"Psychiatr Serv"},{"issue":"10","key":"2661_CR23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","volume":"64","author":"S Saha","year":"2007","unstructured":"Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123\u201331.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"2661_CR24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0447.2012.01835.x","volume":"125","author":"G L\u00e4ngle","year":"2012","unstructured":"L\u00e4ngle G, Steinert T, Weiser P, Schepp W, Jaeger S, Pfiffner C, Frasch K, Eschweiler G, Messer T, Croissant D. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand. 2012;125(5):372\u201381.","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"2661_CR25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1192\/pb.26.5.170","volume":"26","author":"D Taylor","year":"2002","unstructured":"Taylor D, Mir S, Mace S, Whiskey E. Co-prescribing of atypical and typical antipsychotics\u2014prescribing sequence and documented outcome. Psychiatr Bull. 2002;26(5):170\u20132.","journal-title":"Psychiatr Bull"},{"issue":"1","key":"2661_CR26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/oxfordjournals.schbul.a033303","volume":"24","author":"AF Lehman","year":"1998","unstructured":"Lehman AF, Steinwachs DM, Dixon LB, Postrado L, Scott JE, Fahey M, Fischer P, Hoch J, Kasper JA, Lyles A. Patterns of usual care for schizophrenia: initial results from the schizophrenia patient outcomes research team (PORT) client survey. Schizophr Bull. 1998;24(1):11.","journal-title":"Schizophr Bull"},{"issue":"4","key":"2661_CR27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","volume":"161","author":"F Centorrino","year":"2004","unstructured":"Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700\u20136.","journal-title":"Am J Psychiatry"},{"key":"2661_CR28","volume-title":"Psychosis and schizophrenia in adults: treatment and management","author":"National Institute for Clinical Excellence","year":"2014","unstructured":"National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: treatment and management. 2014."},{"issue":"5","key":"2661_CR29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR, Schizophrenia consensus Group of the British Association for psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567\u2013620.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"2661_CR30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N. Royal Australian and new Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410\u201372.","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"2661_CR31","first-page":"122","volume":"25","author":"MA Bujang","year":"2018","unstructured":"Bujang MA, Sa'at N, Sidik T, Joo LC. Sample size guidelines for logistic regression from observational studies with large population: emphasis on the accuracy between statistics and parameters based on real life clinical data. Malays J Med Sci. 2018;25(4):122\u201330.","journal-title":"Malays J Med Sci"},{"key":"2661_CR32","volume-title":"The Maudsley prescribing guidelines in psychiatry, 12th edn: John Wiley & Sons","author":"D Taylor","year":"2015","unstructured":"Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry, 12th edn: John Wiley & Sons; 2015."},{"key":"2661_CR33","volume-title":"British National Formulary (BNF) 70","author":"Joint Formulary Committee","year":"2015","unstructured":"Joint Formulary Committee. British National Formulary (BNF) 70. London: BMJ Publishing and the Royal Pharmaceutical Society; 2015."},{"key":"2661_CR34","doi-asserted-by":"crossref","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Res. 2012;138(1):18\u201328.","DOI":"10.1016\/j.schres.2012.03.018"},{"issue":"9","key":"2661_CR35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/00048674.2011.594947","volume":"45","author":"SA Hollingworth","year":"2011","unstructured":"Hollingworth SA, Lie DC, Siskind DJ, Byrne GJ, Hall WD, Whiteford HA. Psychiatric drug prescribing in elderly Australians: tme for action. Aust NZ J Psychiatry. 2011;45(9):705\u20138.","journal-title":"Aust NZ J Psychiatry"},{"issue":"11","key":"2661_CR36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1192\/pb.23.11.661","volume":"23","author":"PJ Tyson","year":"1999","unstructured":"Tyson PJ, Mortimer AM, Wheeler JA. High-dose antipsychotic treatment in clinical practice: a review, audit and survey of consultant psychiatrist opinions. Psychiatr Bull. 1999;23(11):661\u20134.","journal-title":"Psychiatr Bull"},{"key":"2661_CR37","unstructured":"Robinson J. Challenging the stigma. Pharmaceut J. 2017;299(7907) online."},{"issue":"10","key":"2661_CR38","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.3390\/ijerph111010967","volume":"11","author":"M Rubio-Valera","year":"2014","unstructured":"Rubio-Valera M, Chen TF, O'Reilly CL. New roles for pharmacists in community mental health care: a narrative review. Int J Environ Res Public Health. 2014;11(10):10967\u201390.","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"2661_CR39","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5694\/mja15.00782","volume":"203","author":"S Allison","year":"2015","unstructured":"Allison S, Bastiampillai T. Mental health services reach the tipping poiont in Australian acute hospitals. Med J Aust. 2015;203(11):432\u20134.","journal-title":"Med J Aust"},{"issue":"10067","key":"2661_CR40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(17)30149-6","volume":"389","author":"P Tyrer","year":"2017","unstructured":"Tyrer P, Sharfstein S, O'Reilly R, Allison S, Bastiampillai T. Psychiatric hospital beds: an Orwellian crisis. Lancet. 2017;389(10067):363.","journal-title":"Lancet"},{"key":"2661_CR41","unstructured":"Australasian College of Emergency Medicine and Royal Australian and New Zealand College of Psychiatrists. Mental Health In The Emergency Department: Consensus Statement. Victoria: Australasian College of Emergency Medicine (ACEM); 2019. cited 2019 6th November]. https:\/\/acem.org.au\/getmedia\/0309ba59-d37b-478b-b5c9-e96b272ff837\/Consensus-Satement-110419). Accessed 6 Nov 2019."},{"issue":"5","key":"2661_CR42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1440-1614.2002.01069.x","volume":"36","author":"J Geffen","year":"2002","unstructured":"Geffen J, Sorensen L, Stokes J, Cameron A, Roberts MS, Geffen L. Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals. Aust N Z J Psychiatry. 2002;36(5):649\u201356.","journal-title":"Aust N Z J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02661-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02661-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T19:38:24Z","timestamp":1623353904000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02661-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2661"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02661-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for the retrospective study was obtained from Griffith University (HSV\/04\/15\/HREC) and a District Health Board (HREC\/14\/QPAH\/465) Human Research Ethics Committee. The ethics approval included a waiver of consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TT is an employee with the hospital service at the study site in Queensland.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}